We intend to capitalize on the deep expertise, experience and network of our management team and our board of directors to effect a successful business combination, with a focus on opportunities in the global energy transition ecosystem. (Incorporated in the Cayman Islands) Our sponsor is an affiliate of Denham Capital Management LP, a private equity […]

(Note: JE Cleantech Holdings Limited priced its IPO on April 21, 2022, by selling 3.75 million shares, the same number as in the prospectus, at $4 each – the expected IPO price – to raise $15 million. Of the 3.75 million shares sold: The company offered 3.0 million shares and the other 750,000 shares came […]

We intend to focus on businesses in Asia (excluding China, Hong Kong and Macau) with enterprise values between $200 million and $600 million. (Incorporated in the Cayman Islands) (Note: TenX Keane Acquisition priced its SPAC IPO on Oct. 13, 2022, in line with the terms in its prospectus: 6.0 million units at $10.00 each to […]

We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. (Incorporated in Delaware) Our product candidates are derived from donor cells (allogeneic) rather than a patient’s own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient’s treatment […]

(Note: This is NOT an IPO. This is a NASDAQ uplisting from the Tel Aviv Stock Exchange. IPOScoop has NO CALL on uplistings. This public offering/uplisting is a unit offering with proposed symbol “SVRE” for the stock and proposed symbol “SVREW” for the warrant. Each unit consists of one American Depositary Share (ADS) and one […]

(Note: This is an IPO unit offering. IPOScoop has NO CALL on unit IPOs. Locafy Limited is offering 1.82 million units – up to $10 million in estimated IPO proceeds – at an IPO price expected to be between $4.50 and $6.50 per unit, according to its F-1/A filing dated March 7, 2022. The assumed […]

We are a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). That target has been found on an expanding number of pathogens. While the ultimate decision on the safety and efficacy of our therapeutics […]

We intend to focus on the entertainment and real estate sectors, including experiential entertainment. (Incorporated in the Cayman Islands) Jonathan Goldstein, the founder and CEO of Cain International, is our chairman, CEO and CFO. (Note: Cain Acquisition filed to go public in March 2021 and withdrew its SPAC IPO registration on March 7, 2022.)

We believe that we are a world leading entrepreneur Edtech and education group. Our mission is to disrupt the current education model with a student-centered, lifelong learning curriculum that prepares students with the leadership, entrepreneurial and life skills to succeed in today’s market. To help achieve our mission, we are growing from a Pre-IPO Group […]

We are a pre-clinical biopharmaceutical company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. Our research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which we believe plays a key role in the pathology of these inflammatory eye diseases of high unmet medical […]